TrialInvestigational new drugs2013

A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.

Sil Kordes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.